Thiogenesis Therapeutics Corp
Q8M
Company Profile
Business description
Thiogenesis Therapeutics Corp is a clinical-stage biotech company. The Company is developing thiol-active therapeutic compounds, that are prodrugs, used to treat unmet pediatric medical needs. TTI-0102, the Company’s compound, was developed to address the obstacles facing previous thiol-based drugs, their short half-live, and side effects and it's initial applications are for mitochondrial disease, Rett syndrome, and pediatric NASH.
Contact
4 King Street West
Suite 401
TorontoONM5H 1B6
CANT: +1 647 846-7766
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
Stocks News & Analysis
stocks
10 of the cheapest global companies with wide moats
These undervalued stocks of high-quality companies could be attractive investments today.
stocks
Bookworm: Buy and hold inspiration from an unlikely source
Ben Graham was the king of flipping deep value stocks. The best investment of his life came from something very different.
stocks
3 ASX shares to avoid
These shares have surged in price in the last year but are significantly overvalued according to our analysts.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,082.10 | 68.80 | 0.86% |
| CAC 40 | 8,052.36 | 24.08 | 0.30% |
| DAX 40 | 23,031.39 | 44.57 | 0.19% |
| Dow JONES (US) | 41,488.19 | 674.62 | 1.65% |
| FTSE 100 | 8,655.43 | 23.10 | 0.27% |
| HKSE | 24,145.57 | 185.59 | 0.77% |
| NASDAQ | 17,754.09 | 105.64 | 0.60% |
| Nikkei 225 | 37,396.52 | 343.42 | 0.93% |
| NZX 50 Index | 12,166.14 | 100.11 | -0.82% |
| S&P 500 | 5,638.94 | 117.42 | 2.13% |
| S&P/ASX 200 | 7,854.10 | 64.40 | 0.83% |
| SSE Composite Index | 3,426.13 | 6.57 | 0.19% |